Impact ledger
GSK plc (GSK)
20 events mapped to this ticker since 2026-06-17.
Assumption changes
| Date | Assumption | Direction | Magnitude | Conf. |
|---|---|---|---|---|
| 2026-06-25 | net_debt | Bearish | — | 0.70 |
| 2026-06-25 | interest_expense | Bearish | — | 0.70 |
| 2026-06-24 | share_count | Bullish | — | 0.70 |
| 2026-06-24 | net_debt | Bullish | — | 0.70 |
| 2026-06-24 | revenue | Bullish | — | 0.70 |
Event impact log
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-07-15 | Event | Strategic acquisition to enhance oncology pipeline and future revenue growth, balanced by integration costs and acquisition premium. | mixed | 1-5y | 0.60 |
| 2026-07-15 | Event | Strategic acquisition to enhance oncology pipeline and future revenue streams, offset by immediate integration costs and acquisition premium. | mixed | 1-5y | 0.60 |
| 2026-07-15 | Event | The amendment suggests the acquisition is progressing, which could lead to future integration costs or benefits. The immediate impact on a large acquirer is typically minimal unless the terms significantly change. | watch | 1-3m | 0.20 |
| 2026-07-15 | Event | Acquisition of a promising oncology pipeline asset, potentially increasing future revenue streams but also incurring significant upfront costs and integration risks. | mixed | 1-5y | 0.60 |
| 2026-07-15 | Event | Strategic acquisition to enhance pipeline and market position, but with associated acquisition costs and integration risks. | mixed | 1-5y | 0.60 |
| 2026-07-15 | Event | Acquisition cost adjustment, integration risk, and potential for pipeline enhancement. | watch | 1-3m | 0.60 |
| 2026-07-15 | Event | Strategic acquisition of oncology assets to bolster pipeline and future revenue growth, offset by acquisition costs and integration risks. | mixed | 1-5y | 0.60 |
| 2026-07-13 | Event | Increased competition in the global vaccine market, particularly for emerging infectious diseases, potentially impacting future market share or pricing power for similar products. | watch | 1-5y | 0.30 |
| 2026-07-08 | Event | Strategic acquisition, potential for R&D pipeline enhancement and integration costs | watch | 1-3m | 0.60 |
| 2026-07-08 | Event | Direct M&A activity; amendment could signal negotiation progress or adjustments to terms, impacting deal certainty and cost. | mixed | 1-3m | 0.60 |
| 2026-06-29 | Event | Indirect competitive landscape shift in the COPD market; potential for increased competition or strategic responses. | watch | 3-12m | 0.20 |
| 2026-06-29 | Event | Increased competition or market dynamics in the COPD market, potential for future M&A activity in the respiratory space. | watch | 3-12m | 0.30 |
| 2026-06-29 | Event | Potential indirect impact on YUPELRI's market position or sales strategy, as GSK is a key partner for the drug. | watch | 3-12m | 0.30 |
| 2026-06-25 | Event | Strategic acquisition of pipeline assets, potential for future revenue growth offset by acquisition cost and integration risk. | watch | 1-3m | 0.60 |
| 2026-06-25 | Event | Strategic acquisition, pipeline expansion, and financial leverage | watch | 1-5y | 0.60 |
| 2026-06-25 | Event | Increased demand for Cervarix, GSK's HPV vaccine, benefiting from overall market expansion and government mandates. | Bullish | 1-5y | 0.70 |
| 2026-06-24 | Event | Strategic acquisition to enhance pipeline and market position in oncology. The financial impact depends on the strategic value of Nuvalent's assets and the integration success. | watch | 1-5y | 0.60 |
| 2026-06-24 | Event | Acquisition financing, integration risk, pipeline enhancement | watch | 1-3m | 0.60 |
| 2026-06-24 | Event | Strategic acquisition of pipeline assets; potential for integration costs and dilution if financed via equity, or increased debt if financed via debt. | watch | 1-3m | 0.60 |
| 2026-06-17 | Event | Increased competition in the flu vaccine market, potential for market share shifts. | watch | 3-12m | 0.40 |
This ledger is regenerated from Market Ontology's public event pipeline. For live alerts on new assumption changes for GSK, start a trial or view the GSK entity page.